MAP2K7 and acute lymphoblastic leukemia: Targeting this pathway may be a novel therapeutic approach for drug resistant leukemia, which is often cross-resistant to multiple chemotherapeutic drugs.52 With relapsed T-ALL being a rare entity, it is fortunate that numerous compounds targeting the Ras/Raf/MEK pathway, such as the small molecules trametinib or selumetinib, have been tested in other conditions and could potentially be repurposed for the treatment of T-ALL.